SARS-CoV-2 infection depends on viral polyprotein processing, an event catalyzed by the main proteinase Mpro. The solution of the SARS-CoV-2 Mpro tridimensional structure in the last month allowed the investigation of potential inhibitors of viral replication. As objective, this work aims to provide first evidences of the applicability of commercial y approved drugs to treat COVID-19. As methods used in this research: We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Thereby we have as findings that, The higher scores interactions include antiviral components and drugs classified as coagulation modifiers, ACE and dipeptidyl peptidase 4 inhibitors, antimigraine agents, antihistamine. And finally as main conclusions: Our result evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV main protease Mpro and human coagulation factors thrombin and Factor Xa.